Journal of Zhejiang University

Bio-Design and Manufacturing 2026 Vol.9 No.3 P.579 - 598

Design and manufacturing of structurally variant nanocarriers for boosting localized chemotherapy against melanoma

Author(s): Timofey E. Karpov,Anna Rogova,Yulia A. Tishchenko,Irina A. Gorbunova,Radmila R. Sergeeva,Sofya V. Faizullina,Thanh Son Cam,Konstantin Chebyshev,Anastasia S. Khapugina,Eugenia J. Platonova,Ivan N. Gaponenko,Alena I. Shakirova,Sergei A. Shipilovskikh,Alexander S. Timin
Affiliation(s): 1. Institute of Biomedical Systems and Biotechnology, Peter the Great St. Petersburg Polytechnic University, St. Petersburg, 195251, Russian Federation more
Corresponding email(s): karpov_te@spbstu.ru, karpov_te@spbstu.ru, karpov_te@spbstu.ru
Key Words: Inorganic and organic nanoparticles, Physicochemical features, Drug loading and release, Melanoma, Chemotherapy, Clinical translation

Share this article to： More <<< Previous Article \|Next Article >>>

Timofey E. Karpov. Design and manufacturing of structurally variant nanocarriers for boosting localized chemotherapy against melanoma[J]. Journal of Zhejiang University Science D, 2026, 9(3): 579 - 598.

@article{title="Design and manufacturing of structurally variant nanocarriers for boosting localized chemotherapy against melanoma",
author="Timofey E. Karpov",
journal="Journal of Zhejiang University Science D",
volume="9",
number="3",
pages="579 - 598",
year="2026",
publisher="Zhejiang University Press & Springer",
doi="10.1631/bdm.2500283"
}

%0 Journal Article
%T Design and manufacturing of structurally variant nanocarriers for boosting localized chemotherapy against melanoma
%A Timofey E. Karpov
%J Journal of Zhejiang University SCIENCE D
%V 9
%N 3
%P 579 - 598
%@ 1869-1951
%D 2026
%I Zhejiang University Press & Springer
%DOI 10.1631/bdm.2500283

TY - JOUR
T1 - Design and manufacturing of structurally variant nanocarriers for boosting localized chemotherapy against melanoma
A1 - Timofey E. Karpov
J0 - Journal of Zhejiang University Science D
VL - 9
IS - 3
SP - 579
EP - 598
%@ 1869-1951
Y1 - 2026
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/bdm.2500283

Abstract
Chinese Summary
Academic Network
Reviewer Comment

Abstract: Nanomedicine has enormous potential in the diagnosis and treatment of malignant neoplasms. However, the clinical translation of various nanoparticles (NPs) as drug delivery systems (DDSs) for tumor therapy remains poor. The main bottleneck is the limited database on the correlation between the design of NPs with unique physicochemical features and their therapeutic efficiency. In this study, we aim to design and investigate structurally variant nanocarriers composed of polylactide (PLA), silicon dioxide (SiO2), calcium carbonate (CaCO3), and barium carbonate (BaCO3) to reveal the relationship between their physicochemical features and therapeutic effectiveness against melanoma in vitro and in vivo. Specifically, we (1) examined their morphology, size, and structural characteristics; (2) evaluated colloidal stability; (3) verified the drug-loading and release efficiency of a 2-aminothiophene scaffold (2AmT); (4) investigated cellular uptake and tumor spheroid penetration efficiency; (5) analyzed in vivo biodistribution; and (6) estimated therapeutic efficiency. The main characteristics of inorganic and organic NPs were collected and compared systematically. Considering the advantages and drawbacks of each NP type, the following tumor growth inhibition against melanoma was observed: CaCO3(87.9%–93.4% for 0.4 g/kg of 2AmT)>SiO2(75.6%–93.2% for 0.4 g/kg of 2AmT)>PLA (80.3%–88.2% for 0.4 g/kg of 2AmT)>BaCO3(58.8%–83.7% for 0.4 g/kg of 2AmT). Thus, this study contributes to the development of fundamental nanomedicine and accelerates the clinical translation of nanocarriers for effective melanoma therapy.The alternative text for this image may have been generated using AI.

Design and manufacturing of structurally variant nanocarriers for boosting localized chemotherapy against melanoma

纳米医学在恶性肿瘤的诊断与治疗中展现出巨大潜力。然而, 各类纳米颗粒 (nanoparticles, NPs) 作为药物递送系统 (drug delivery systems, DDSs) 在肿瘤治疗中的临床转化仍然有限, 其主要瓶颈在于缺乏关于具有特定理化特性的纳米颗粒设计与其治疗效果之间关联的系统性数据。本研究设计并构建了由聚乳酸 (PLA)、二氧化硅 (SiO2)、碳酸钙 (CaCO3) 和碳酸钡 (BaCO3) 组成的结构可变纳米载体, 旨在揭示其理化特性与黑色素瘤治疗效果之间的关系 (包括体外和体内)。具体而言, 本研究: (1) 表征了纳米颗粒的形貌、尺寸及结构特征; (2) 评估其胶体稳定性; (3) 验证了基于 2-氨基噻吩骨架药物 (2AmT) 的载药和释放性能; (4) 研究其细胞摄取及肿瘤球体穿透能力; (5) 分析体内生物分布; (6) 评估其治疗效果。通过对有机与无机纳米颗粒关键特性的系统比较, 结果表明, 在 0.4 g/kg2AmT 剂量下, 对黑色素瘤的肿瘤生长抑制效果依次为: CaCO3(87.9%–93.4%) >SiO2(75.6%–93.2%) >PLA (80.3%–88.2%) >BaCO3(58.8%–83.7%)。本研究为纳米医学基础研究提供了重要依据, 并有助于推动高效黑色素瘤纳米载体的临床转化。
Inorganic and organic nanoparticles; Physicochemical features; Drug loading and release; Melanoma; Chemotherapy; Clinical translation